Paradigm Biopharmaceuticals to Return $2 Million of Funds to Obsidian Global

MT Newswires Live09-24

Paradigm Biopharmaceuticals (ASX:PAR) agreed to return the $2 million of funds it recently received from Obsidian Global under a fourth-tranche drawdown of its convertible note facility, according to a Thursday filing with the Australian bourse.

The 2 million convertible notes issued in connection with the drawdown will be cancelled, and no premium, redemption amount, or other amount is payable by Paradigm under the arrangement, per the filing.

The development follows the interim efficacy result for Paradigm's phase 3 trial of injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis failing to reach the threshold required for the study to proceed.

The company is reviewing data to better understand what impact that trial result will have on its financial position and future operations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2669541554?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-24 14:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669541554","market":"sg","top_or_hot":-1,"title":"Paradigm Biopharmaceuticals to Return $2 Million of Funds to Obsidian Global","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PBIGF\">Paradigm Biopharmaceuticals</a> (ASX:PAR) agreed to return the $2 million of funds it recently received from Obsidian Global under a fourth-tranche drawdown of its convertible note facility, according to a Thursday filing with the Australian bourse.</p><p>The 2 million convertible notes issued in connection with the drawdown will be cancelled, and no premium, redemption amount, or other amount is payable by Paradigm under the arrangement, per the filing.</p><p>The development follows the interim efficacy result for Paradigm's phase 3 trial of injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis failing to reach the threshold required for the study to proceed.</p><p>The company is reviewing data to better understand what impact that trial result will have on its financial position and future operations.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Paradigm Biopharmaceuticals to Return $2 Million of Funds to Obsidian Global</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nParadigm Biopharmaceuticals to Return $2 Million of Funds to Obsidian Global\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-24 14:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PBIGF\">Paradigm Biopharmaceuticals</a> (ASX:PAR) agreed to return the $2 million of funds it recently received from Obsidian Global under a fourth-tranche drawdown of its convertible note facility, according to a Thursday filing with the Australian bourse.</p><p>The 2 million convertible notes issued in connection with the drawdown will be cancelled, and no premium, redemption amount, or other amount is payable by Paradigm under the arrangement, per the filing.</p><p>The development follows the interim efficacy result for Paradigm's phase 3 trial of injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis failing to reach the threshold required for the study to proceed.</p><p>The company is reviewing data to better understand what impact that trial result will have on its financial position and future operations.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2669541554","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669541554","pubTimestamp":1790230359,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Paradigm Biopharmaceuticals  agreed to return the $2 million of funds it recently received from Obsidian Global under a fourth-tranche drawdown of its convertible note facility, according to a Thursday filing with the Australian bourse.The 2 million convertible notes issued in connection with the drawdown will be cancelled, and no premium, redemption amount, or other amount is payable by Paradigm under the arrangement, per the filing.The development follows the interim efficacy result for Paradigm's phase 3 trial of injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis failing to reach the threshold required for the study to proceed.The company is reviewing data to better understand what impact that trial result will have on its financial position and future operations.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","PAR.AU":"PARADIGM BIOPHARMACEUTICALS","BK7067":"生物科技"},"translate_title":"Paradigm Biopharmaceuticals 将向 Obsidian Global 返还 200 万美元资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAR.AU":1},"content_text":"Paradigm Biopharmaceuticals (ASX:PAR) agreed to return the $2 million of funds it recently received from Obsidian Global under a fourth-tranche drawdown of its convertible note facility, according to a Thursday filing with the Australian bourse.The 2 million convertible notes issued in connection with the drawdown will be cancelled, and no premium, redemption amount, or other amount is payable by Paradigm under the arrangement, per the filing.The development follows the interim efficacy result for Paradigm's phase 3 trial of injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis failing to reach the threshold required for the study to proceed.The company is reviewing data to better understand what impact that trial result will have on its financial position and future operations.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2669541554","isCrawlerRequest":true}